KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Short-term Investments (2021 - 2025)

AbCellera Biologics' Short-term Investments history spans 5 years, with the latest figure at $25.0 million for Q3 2025.

  • For the quarter ending Q3 2025, Short-term Investments changed 0.0% year-over-year to $25.0 million, compared with a TTM value of $25.0 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $25.0 million, changed 0.0% over the prior year.
  • Short-term Investments for Q3 2025 was $25.0 million at AbCellera Biologics, roughly flat from $25.0 million in the prior quarter.
  • The five-year high for Short-term Investments was $25.0 million in Q4 2021, with the low at $25.0 million in Q4 2021.
  • Average Short-term Investments over 5 years is $25.0 million, with a median of $25.0 million recorded in 2021.
  • Biggest YoY gain for Short-term Investments was 0.0% in 2022; the steepest drop was 0.0% in 2022.
  • Tracing ABCL's Short-term Investments over 5 years: stood at $25.0 million in 2021, then changed by 0.0% to $25.0 million in 2022, then changed by 0.0% to $25.0 million in 2023, then changed by 0.0% to $25.0 million in 2024, then changed by 0.0% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Short-term Investments are $25.0 million (Q3 2025), $25.0 million (Q2 2025), and $25.0 million (Q1 2025).